April 2014 | The Journal of Targeted Therapies in Cancer

NCCN Guidelines Include Obinutuzumab in CLL

May 12, 2014

Clinical Articles

Amid advances in targeted therapies for patients with chronic lymphocytic leukemia (CLL), researchers also have been making strides in the realm of chemoimmunotherapy regimens for the disease.

Ramucirumab: A Novel Antiangiogenic Agent for Gastric Cancer and Gastroesophageal Junction Cancer

May 06, 2014

Clinical Articles

Advanced gastric cancer and gastroesophageal junction cancers are highly aggressive cancers with poor prognosis and limited treatment options. The VEGF pathway has been one of the key signaling pathways under investigation for these cancers.

Androgen-Targeting Therapies Increasing in CRPC

May 01, 2014

Clinical Articles

A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the treatment of CRPC.

Immunotherapies in CRPC: Progress Evident but Not Without Challenges

April 24, 2014

Clinical Articles

Increasing efficacy with cancer vaccines, oncolytic viruses, and checkpoint inhibitors in clinical trials led to immunotherapy, as a whole, being deemed Breakthrough of the Year by Science magazine in 2013.

MEK Inhibitors

April 23, 2014

Clinical Articles

The RAS-RAF-MEK-extracellular signal–regulated kinase 1 and 2 (ERK1/2) pathway is the most mutated pathway in human cancer. Thus, components of this pathway have been seen as promising targets for cancer therapy.